scholarly journals Copy Neutral LOH Affecting the Entire Chromosome 6 is a Frequent Mechanism of HLA Class I Alterations in Cancer

Cancers ◽  
2021 ◽  
Vol 13 (20) ◽  
pp. 5046
Author(s):  
Maria Garrido ◽  
Francisco Perea ◽  
Jose Vilchez ◽  
Teresa Rodriguez ◽  
Per Anderson ◽  
...  

Total or partial loss of HLA class I antigens reduce the recognition of specific tumor peptides by cytotoxic T lymphocytes favoring cancer immune escape during natural tumor evolution. These alterations can be caused by genomic defects, such as loss of heterozygosity at chromosomes 6 and 15 (LOH-6 and LOH-15), where HLA class I genes are located. There is growing evidence indicating that LOH in HLA contributes to the immune selection of HLA loss variants and influences the resistance to immunotherapy. Nevertheless, the incidence and the mechanism of this chromosomal aberration involving HLA genes has not been systematically assessed in different types of tumors and often remains underestimated. Here, we used SNP arrays to investigate the incidence and patterns of LOH-6 and LOH-15 in a number of human cancer cell lines and tissues of different histological types. We observed that LOH in HLA is a common event in cancer samples with a prevalence of a copy neutral type of LOH (CN-LOH) that affects entire chromosome 6 or 15 and involves chromosomal duplications. LOH-6 was observed more often and was associated with homozygous HLA genotype and partial HLA loss of expression. We also discuss the immunologic and clinical implications of LOH in HLA on tumor clonal expansion and association with the cancer recurrence after treatment.

2020 ◽  
Author(s):  
Megan Ren ◽  
Mathias Viard ◽  
Arman Bashirova ◽  
Meredith Yeager ◽  
Lisa Mirabello ◽  
...  

1984 ◽  
pp. 643-643
Author(s):  
F. H. J. Claas ◽  
R. Castelli-Visser ◽  
B. M. de Jongh ◽  
J. J. van Rood ◽  
W. M. A. Verhoeven ◽  
...  

2020 ◽  
Vol 8 (1) ◽  
pp. e000410
Author(s):  
Jonathan S Cebon ◽  
Martin Gore ◽  
John F Thompson ◽  
Ian D Davis ◽  
Grant A McArthur ◽  
...  

BackgroundTo compare the clinical efficacy of New York Esophageal squamous cell carcinoma-1 (NY-ESO-1) vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in a randomized, double-blind phase II study in participants with fully resected melanoma at high risk of recurrence.MethodsParticipants with resected stage IIc, IIIb, IIIc and IV melanoma expressing NY-ESO-1 were randomized to treatment with three doses of NY-ESO-1/ISCOMATRIX or ISCOMATRIX adjuvant administered intramuscularly at 4-week intervals, followed by a further dose at 6 months. Primary endpoint was the proportion free of relapse at 18 months in the intention-to-treat (ITT) population and two per-protocol populations. Secondary endpoints included relapse-free survival (RFS) and overall survival (OS), safety and NY-ESO-1 immunity.ResultsThe ITT population comprised 110 participants, with 56 randomized to NY-ESO-1/ISCOMATRIX and 54 to ISCOMATRIX alone. No significant toxicities were observed. There were no differences between the study arms in relapses at 18 months or for median time to relapse; 139 vs 176 days (p=0.296), or relapse rate, 27 (48.2%) vs 26 (48.1%) (HR 0.913; 95% CI 0.402 to 2.231), respectively. RFS and OS were similar between the study arms. Vaccine recipients developed strong positive antibody responses to NY-ESO-1 (p≤0.0001) and NY-ESO-1-specific CD4+and CD8+responses. Biopsies following relapse did not demonstrate differences in NY-ESO-1 expression between the study populations although an exploratory study demonstrated reduced (NY-ESO-1)+/Human Leukocyte Antigen (HLA) class I+double-positive cells in biopsies from vaccine recipients performed on relapse in 19 participants.ConclusionsThe vaccine was well tolerated, however, despite inducing antigen-specific immunity, it did not affect survival endpoints. Immune escape through the downregulation of NY-ESO-1 and/or HLA class I molecules on tumor may have contributed to relapse.


1986 ◽  
Vol 15 (4) ◽  
pp. 347-356 ◽  
Author(s):  
Frans H.J. Claas ◽  
Jan M. van Ree ◽  
Wim M.A. Verhoeven ◽  
Jan J. van der Poel ◽  
Willem Verduyn ◽  
...  

2004 ◽  
Vol 171 (2) ◽  
pp. 885-889 ◽  
Author(s):  
DEREK ATKINS ◽  
SOLDANO FERRONE ◽  
GERD E. SCHMAHL ◽  
STEFAN STÖRKEL ◽  
BARBARA SELIGER

Sign in / Sign up

Export Citation Format

Share Document